Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.Sub-event
- GSK's failed trials opened a market niche for Trevi Therapeutics.Sub-event
GSK collaboration revenue increased total revenue; FDA action needed for tepipenem HBR approval.1 source
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
Spero Therapeutics (United States)
company in Cambridge, United States
Nothing else this week.
- FDA
Related events
- FDA approval boosts the Korean drug industry, driving market attention for companies like SamChunDang Pharm.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
Coverage
Newest first; wire copies grouped- GuruFocus.comSpero Therapeutics Inc (SPRO) Q2 2025 Earnings Call Highlights: Tepipenem HBR Trial Success and ... Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the